Advanced search
Publication Cover
mAbs Volume 3, 2011 - Issue 1
Submit an article Journal homepage
6,410
Views
217
CrossRef citations to date
0
Altmetric
Report

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

What have we learned?

Rong Deng Department of Pharmacokinetic and Pharmacodynamic Sciences; Genentech, Inc.; South San Francisco, CA USACorrespondence[email protected]
,
Suhasini Iyer Department of Pharmacokinetic and Pharmacodynamic Sciences; Genentech, Inc.; South San Francisco, CA USA
,
Frank-Peter Theil Department of Pharmacokinetic and Pharmacodynamic Sciences; Genentech, Inc.; South San Francisco, CA USA
,
Deborah L. Mortensen Department of Pharmacokinetic and Pharmacodynamic Sciences; Genentech, Inc.; South San Francisco, CA USA
,
Paul J. Fielder Department of Pharmacokinetic and Pharmacodynamic Sciences; Genentech, Inc.; South San Francisco, CA USA
&
Saileta Prabhu Department of Pharmacokinetic and Pharmacodynamic Sciences; Genentech, Inc.; South San Francisco, CA USA
Pages 61-66 | Received 13 Oct 2010, Accepted 30 Sep 2010, Published online: 01 Jan 2011

Citations (217)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (42)

Joshuaine Grant, Fei Hua, Joshua F. Apgar, John M. Burke & Diana H. Marcantonio. (2023) Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions. mAbs 15:1.
Read now
Jinjie He, Weijuan Du, Haijing Yang, Jingjing Wang, Chenghang Cai, Qingyang Ma, Nanyang Li, Jicheng Yu, Xiaojie Wu, Jufang Wu, Yuancheng Chen, Guoying Cao & Jing Zhang. (2023) Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study. Expert Opinion on Investigational Drugs 32:7, pages 669-675.
Read now
Karelle Ménochet, Hongbin Yu, Bonnie Wang, Jay Tibbitts, Cheng-Pang Hsu, Amrita V. Kamath, Wolfgang F. Richter & Andreas Baumann. (2022) Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper. mAbs 14:1.
Read now
Hong Xiang, Abigael G. Chan, Ago Ahene, David I. Bellovin, Rong Deng, Amy W. Hsu, Ursula Jeffry, Servando Palencia, Janine Powers, James Zanghi & Helen Collins. (2021) Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. mAbs 13:1.
Read now
Eva Germovsek, Ming Cheng & Craig Giragossian. (2021) Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings. mAbs 13:1.
Read now
Boris Grinshpun, Nels Thorsteinson, Joao NS Pereira, Friedrich Rippmann, David Nannemann, Vanita D. Sood & Yves Fomekong Nanfack. (2021) Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies. mAbs 13:1.
Read now
Inja Waldhauer, Valeria Gonzalez-Nicolini, Anne Freimoser-Grundschober, Tapan K Nayak, Linda Fahrni, Ralf J. Hosse, Danny Gerrits, Edwin J. W. Geven, Johannes Sam, Sabine Lang, Esther Bommer, Virginie Steinhart, Elisabeth Husar, Sara Colombetti, Erwin Van Puijenbroek, Markus Neubauer, J. Mark Cline, Pradeep K. Garg, Gregory Dugan, Federica Cavallo, Gonzalo Acuna, Jehad Charo, Volker Teichgräber, Stefan Evers, Otto C. Boerman, Marina Bacac, Ekkehard Moessner, Pablo Umaña & Christian Klein. (2021) Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. mAbs 13:1.
Read now
Jiaxue Wang, Suping Niu, Wenliang Dong, Li Wei, Lun Ou, Tan Zhang, Liangbi Zhang, Xiaoyan Nie, Qian Wang, Tiantian Shen, Qi Wang, Lin Xia, Gang Liu, Jiting Jin, Qingshan Zheng, Haifeng Song & Yi Fang. (2020) A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. Expert Opinion on Investigational Drugs 29:7, pages 755-762.
Read now
Songmao Zheng, Jin Niu, Brian Geist, Damien Fink, Zhenhua Xu, Honghui Zhou & Weirong Wang. (2020) A minimal physiologically based pharmacokinetic model to characterize colon TNF suppression and treatment effects of an anti-TNF monoclonal antibody in a mouse inflammatory bowel disease model. mAbs 12:1.
Read now
Songmao Zheng, Fang Shen, Brian Jones, Damien Fink, Brian Geist, Ivo Nnane, Zhao Zhou, Jeff Hall, Ravi Malaviya, Tatiana Ort & Weirong Wang. (2020) Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A. mAbs 12:1.
Read now
Chunze Li, Cindy Zhang, Zao Li, Divya Samineni, Dan Lu, Bei Wang, Shang-Chiung Chen, Rong Zhang, Priya Agarwal, Bernard M. Fine & Sandhya Girish. (2020) Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. mAbs 12:1.
Read now
Romain Ollier, Paul Wassmann, Thierry Monney, Christelle Ries Fecourt, Sunitha Gn, Vinu C A, Daniel Ayoub, Cian Stutz, Girish S Gudi & Stanislas Blein. (2019) Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development. mAbs 11:8, pages 1464-1478.
Read now
Rong Deng, Chenguang Zhou, Dongwei Li, Hao Cai, Siddharth Sukumaran, Montserrat Carrasco-Triguero, Ola Saad, Denise Nazzal, Christopher Lowe, Saroja Ramanujan & Amrita V. Kamath. (2019) Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate against Staphylococcus aureus. mAbs 11:6, pages 1162-1174.
Read now
Jennifer Ahlberg, Craig Giragossian, Hua Li, Maria Myzithras, Ernie Raymond, Gary Caviness, Christine Grimaldi, Su-Ellen Brown, Rocio Perez, Danlin Yang, Rachel Kroe-Barrett, David Joseph, Chandrasena Pamulapati, Kelly Coble, Peter Ruus, Joseph R. Woska, Rajkumar Ganesan, Steven Hansel & M. Lamine Mbow. (2019) Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5). mAbs 11:5, pages 956-964.
Read now
Shan Chung, Van Nguyen, Yuwen Linda Lin, Julien Lafrance-Vanasse, Suzie J. Scales, Kevin Lin, Rong Deng, Kathi Williams, Gizette Sperinde, Juan Jenny Li, Kai Zheng, Siddharth Sukumaran, Devin Tesar, James A. Ernst, Saloumeh Fischer, Greg A. Lazar, Saileta Prabhu & An Song. (2019) An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans. mAbs 11:5, pages 942-955.
Read now
Nathan D. Trinklein, Duy Pham, Ute Schellenberger, Ben Buelow, Andrew Boudreau, Priya Choudhry, Starlynn C. Clarke, Kevin Dang, Katherine E. Harris, Suhasini Iyer, Brett Jorgensen, Payal P. Pratap, Udaya S. Rangaswamy, Harshad S. Ugamraj, Omid Vafa, Arun P. Wiita, Wim van Schooten, Roland Buelow & Shelley Force Aldred. (2019) Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. mAbs 11:4, pages 639-652.
Read now
Douglas D. Leipold, Isabel Figueroa, Shabkhaiz Masih, Brandon Latifi, Victor Yip, Ben-Quan Shen, Randall C. Dere, Montserrat Carrasco-Triguero, M. Violet Lee, Ola M. Saad, Luna Liu, Jintang He, Dian Su, Keyang Xu, Brian R. Vuillemenot, Steven T. Laing, Melissa Schutten, Katherine R. Kozak, Bing Zheng, Andrew G. Polson & Amrita V. Kamath. (2018) Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia. mAbs 10:8, pages 1312-1321.
Read now
Isabel Figueroa, Doug Leipold, Steve Leong, Bing Zheng, Montserrat Triguero-Carrasco, Aimee Fourie-O'Donohue, Katherine R. Kozak, Keyang Xu, Melissa Schutten, Hong Wang, Andrew G. Polson & Amrita V. Kamath. (2018) Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC. mAbs 10:5, pages 738-750.
Read now
Alison Betts, Anne Keunecke, Tamara J. van Steeg, Piet H. van der Graaf, Lindsay B. Avery, Hannah Jones & Jan Berkhout. (2018) Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. mAbs 10:5, pages 751-764.
Read now
Lindsay B. Avery, Jason Wade, Mengmeng Wang, Amy Tam, Amy King, Nicole Piche-Nicholas, Mania S. Kavosi, Steve Penn, David Cirelli, Jeffrey C. Kurz, Minlei Zhang, Orla Cunningham, Rhys Jones, Brian J. Fennell, Barry McDonnell, Paul Sakorafas, James Apgar, William J. Finlay, Laura Lin, Laird Bloom & Denise M. O'Hara. (2018) Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. mAbs 10:2, pages 244-255.
Read now
Charlotte Bon, Thomas Hofer, Alain Bousquet-Mélou, Mark R. Davies & Ben-Fillippo Krippendorff. (2017) Capacity limits of asialoglycoprotein receptor-mediated liver targeting. mAbs 9:8, pages 1360-1369.
Read now
Miroslav Dostalek, Thomayant Prueksaritanont & Robert F. Kelley. (2017) Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates. mAbs 9:5, pages 756-766.
Read now
Claudia A. Castro Jaramillo, Sara Belli, Anne-Christine Cascais, Sherri Dudal, Martin R. Edelmann, Markus Haak, Marie-Elise Brun, Michael B. Otteneder, Mohammed Ullah, Christoph Funk, Franz Schuler & Silke Simon. (2017) Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms. mAbs 9:5, pages 781-791.
Read now
Kenta Haraya, Tatsuhiko Tachibana & Junichi Nezu. (2017) Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey. Xenobiotica 47:3, pages 194-201.
Read now
Chenguang Zhou, Sophie Lehar, Johnny Gutierrez, Carrie M. Rosenberger, Nina Ljumanovic, Jason Dinoso, Neelima Koppada, Kyu Hong, Amos Baruch, Montserrat Carrasco-Triguero, Ola Saad, Sanjeev Mariathasan & Amrita V. Kamath. (2016) Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice. mAbs 8:8, pages 1612-1619.
Read now
Maria Myzithras, Tammy Bigwarfe, Hua Li, Erica Waltz, Jennifer Ahlberg, Craig Giragossian & Simon Roberts. (2016) Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics. mAbs 8:8, pages 1606-1611.
Read now
Emma Davé, Ralph Adams, Oliver Zaccheo, Bruce Carrington, Joanne E. Compson, Sarah Dugdale, Michael Airey, Sarah Malcolm, Hanna Hailu, Gavin Wild, Alison Turner, James Heads, Kaushik Sarkar, Andrew Ventom, Diane Marshall, Mark Jairaj, Tim Kopotsha, Louis Christodoulou, Miren Zamacona, Alastair D. Lawson, Sam Heywood & David P. Humphreys. (2016) Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding. mAbs 8:7, pages 1319-1335.
Read now
Lindsay B. Avery, Mengmeng Wang, Mania S. Kavosi, Alison Joyce, Jeffrey C. Kurz, Yao-Yun Fan, Martin E. Dowty, Minlei Zhang, Yiqun Zhang, Aili Cheng, Fei Hua, Hannah M. Jones, Hendrik Neubert, Robert J. Polzer & Denise M. O'Hara. (2016) Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. mAbs 8:6, pages 1064-1078.
Read now
Priyanka Gupta, Amrita V. Kamath, Summer Park, Henry Chiu, Jeff Lutman, Mauricio Maia, Man-Wah Tan, Min Xu, Lee Swem & Rong Deng. (2016) Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A . mAbs 8:5, pages 991-997.
Read now
S Dudal, K Subramanian, T Flandre, WS Law, PJ Lowe, A Skerjanec, J-C Genin, M Duval, A Piequet, A Cordier, G Jarai, G Van Heeke, S Taplin, C Krantz, S Jones, AP Warren, FR Brennan, J Sims & P Lloyd. (2015) Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys. mAbs 7:5, pages 829-837.
Read now
Lei Diao & Bernd Meibohm. (2015) Tools for predicting the PK/PD of therapeutic proteins. Expert Opinion on Drug Metabolism & Toxicology 11:7, pages 1115-1125.
Read now
Kenta Haraya, Tatsuhiko Tachibana, Masahiko Nanami & Masaki Ishigai. (2014) Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Xenobiotica 44:12, pages 1127-1134.
Read now
Amrita V Kamath, Victor Yip, Priyanka Gupta, C Andrew Boswell, Daniela Bumbaca, Peter Haughney, Joni Castro, Siao Ping Tsai, Glenn Pacheco, Sarajane Ross, Minhong Yan, Lisa A Damico-Beyer, Leslie Khawli & Ben-Quan Shen. (2014) Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice. mAbs 6:6, pages 1631-1637.
Read now
Bing Li, Devin Tesar, C Andrew Boswell, Hendry S Cahaya, Anne Wong, Jianhuan Zhang, Y Gloria Meng, Charles Eigenbrot, Homer Pantua, Jinyu Diao, Sharookh B Kapadia, Rong Deng & Robert F Kelley. (2014) Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. mAbs 6:5, pages 1255-1264.
Read now
Jasmine P Davda, Michael G Dodds, Megan A Gibbs, Wendy Wisdom & John P Gibbs. (2014) A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design. mAbs 6:4, pages 1094-1102.
Read now
Elliot Offman & Andrea N. Edginton. (2013) Contrasting toxicokinetic evaluations and interspecies pharmacokinetic scaling approaches for small molecules and biologics: applicability to biosimilar development. Xenobiotica 43:6, pages 561-569.
Read now
Yulia Vugmeyster, Cynthia Rohde, Mylene Perreault, Ruth E. Gimeno & Pratap Singh. (2013) Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B. mAbs 5:3, pages 373-383.
Read now
Karen Thudium, Sanela Bilic, Douglas Leipold, William Mallet, Surinder Kaur, Bernd Meibohm, Hans Erickson, Jay Tibbitts, Hong Zhao & Manish Gupta. (2013) American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates. mAbs 5:1, pages 5-12.
Read now
Deborah L. Mortensen, Saileta Prabhu, Eric G. Stefanich, Saloumeh Kadkhodayan-Fischer, Thomas R. Gelzleichter, Dana Baker, Jenny Jiang, Kristin Wallace, Suhasini Iyer, Paul J. Fielder & Wendy S. Putnam. (2012) Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies. mAbs 4:6, pages 724-731.
Read now
Isidro Hötzel, Frank-Peter Theil, Lisa J. Bernstein, Saileta Prabhu, Rong Deng, Leah Quintana, Jeff Lutman, Renuka Sibia, Pamela Chan, Daniela Bumbaca, Paul Fielder, Paul J. Carter & Robert F. Kelley. (2012) A strategy for risk mitigation of antibodies with fast clearance. mAbs 4:6, pages 753-760.
Read now
Yanan Zheng, Devin B. Tesar, Lisa Benincosa, Herbert Birnböck, C. Andrew Boswell, Daniela Bumbaca, Kyra J Cowan, Dimitry M. Danilenko, Ann L. Daugherty, Paul J. Fielder, Hans Peter Grimm, Amita Joshi, Nicole Justies, Gerry Kolaitis, Nicholas Lewin-Koh, Jing Li, Sami McVay, Jennifer O'Mahony, Michael Otteneder, Michael Pantze, Wendy S. Putnam, Zhihua J. Qiu, Jane Ruppel, Thomas Singer, Oliver Stauch, Frank-Peter Theil, Jennifer Visich, Jihong Yang, Yong Ying, Leslie A. Khawli & Wolfgang F. Richter. (2012) Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. mAbs 4:2, pages 243-255.
Read now
Rong Deng, Feng Jin, Saileta Prabhu & Suhasini Iyer. (2012) Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?. Expert Opinion on Drug Metabolism & Toxicology 8:2, pages 141-160.
Read now

Articles from other publishers (175)

Rolf Grempler, Jennifer Ahlberg, Eva Germovsek, Priyanka Gupta, Hua Li, Minu Pilvankar, Ashish Sharma, Peter Stopfer & Steven Hansel. (2023) Human Dose and Pharmacokinetic Predictions for Biologics at Boehringer Ingelheim: A Retrospective Analysis. Advances in Therapy.
Crossref
Miki Yokoyama, Eiko Suzuki, Masataka Oitate & Nobuaki Watanabe. (2023) A Quantitative Prediction Method for the Human Pharmacokinetics of Fc-Fusion Proteins. European Journal of Drug Metabolism and Pharmacokinetics 48:5, pages 541-552.
Crossref
Qiaoning Li, Ling Wang, Jinfeng Zhang, Guorui Zhao, Zhihao Liu, Xinting Ma & Jing Jiang. (2023) Translation of the efficacy of antibody–drug conjugates from preclinical to clinical using a semimechanistic PK / PD model: A case study with RC88 . Clinical and Translational Science 16:7, pages 1232-1242.
Crossref
Rajbharan Yadav, Siddharth Sukumaran, Jeff Lutman, Mayur S. Mitra, Wendy Halpern, Tianhe Sun, A. Francesca Setiadi, Margaret Neighbors, X. Rebecca Sheng, Victor Yip, Ben-Quan Shen, Chang Liu, Lyrialle Han, Ayse Meric Ovacik, Yan Wu, Sara Glickstein, Rebecca Kunder, Joseph R. Arron, Lin Pan, Amrita V. Kamath & Eric G. Stefanich. (2023) Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases. Journal of Pharmaceutical Sciences.
Crossref
Dan Lu, Rajbharan Yadav, Patrick Holder, Eugene Chiang, Shomyseh Sanjabi, Victor Poon, Matthew Bernett, Rajat Varma, Ke Liu, Irene Leung, Liz Bogaert, John Desjarlais, Vittal Shivva, Iraj Hosseini & Saroja Ramanujan. (2023) Complex PK-PD of an engineered IL-15/IL-15Rα–Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics. European Journal of Pharmaceutical Sciences 186, pages 106450.
Crossref
Patrick G. Groothuis, Daniëlle C.H. Jacobs, Inge A.T. Hermens, Désirée Damming, Kim Berentsen, Ellen Mattaar-Hepp, Marloes E.M. Stokman, Tinie van Boekel, Myrthe Rouwette, Monique A.J. van der Vleuten, Aloys Sesink, Fred A. Dijcks, Ruud G.E. Coumans, Jan Schouten, Dirk H. Glaudemans, Daniëlle van Wijk, Marion Blomenröhr, Wendela A. Kappers, Ruud Ubink, Miranda M.C. van der Lee & Wim H.A. Dokter. (2023) Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate. Molecular Cancer Therapeutics 22:6, pages 765-777.
Crossref
Peng Zou. (2023) Predicting Human Bioavailability of Subcutaneously Administered Monoclonal Antibodies Using Non-human Primate Linear Clearance and Antibody Isoelectric Point. The AAPS Journal 25:4.
Crossref
Michael W. Leach & Katherine Hammerman. 2023. Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology. Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology 175 230 .
Kenta Haraya & Tatsuhiko Tachibana. (2022) Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations. BioDrugs 37:1, pages 99-108.
Crossref
Annie Ogasawara, James R. Kiefer, Herman Gill, Eugene Chiang, Shravan Sriraman, Gregory Z. Ferl, James Ziai, Sandra Sanabria Bohorquez, Sebastian Guelman, Xiangdan Wang, Jihong Yang, Minh Michael Phan, Van Nguyen, Shan Chung, Christine Yu, Jeff Tinianow, Stijn Jan Hein Waaijer, Alex De Crespigny, Jan Marik, C. Andrew Boswell, Tanja Zabka, Karin Staflin & Simon-Peter Williams. (2022) Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging 50:2, pages 287-301.
Crossref
Hossein Salimi-Moosavi & Marcus Soto. (2022) A Non-radiometric Approach to Determine Tissue Vascular Blood Volume in Biodistribution Studies. The AAPS Journal 24:6.
Crossref
Sanghwan Ko, Sora Park, Myung Ho Sohn, Migyeong Jo, Byoung Joon Ko, Jung-Hyun Na, Hojin Yoo, Ae Lee Jeong, Kyungsoo Ha, Ju Rang Woo, Chungsu Lim, Jung Hyu Shin, Dohyun Lee, So-Young Choi & Sang Taek Jung. (2022) An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies. Experimental & Molecular Medicine 54:11, pages 1850-1861.
Crossref
Blaise Pasquiers, Salih Benamara, Mathieu Felices, Laurent Nguyen & Xavier Declèves. (2022) Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection. International Journal of Molecular Sciences 23:21, pages 12754.
Crossref
Edmund V. Capparelli, Gbolahan Ajibola, Kenneth Maswabi, Molly P. Holme, Kara Bennett, Kathleen M. Powis, Sikhulile Moyo, Terence Mohammed, Comfort Maphorisa, Michael D. Hughes, Kelly E. Seaton, Georgia D. Tomaras, Shad Mosher, Alison Taylor, Sarah O’Connell, Sandeep Narpala, Adrian Mcdermott, Marina Caskey, Lucio Gama, Shahin Lockman, Patrick Jean-Philippe, Joseph Makhema, Daniel R. Kuritzkes, Mathias Lichterfeld & Roger L. Shapiro. (2022) Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children. JAIDS Journal of Acquired Immune Deficiency Syndromes 91:2, pages 182-188.
Crossref
Hao Cai, Satoko Kakiuchi-Kiyota, Robert Hendricks, Shelly Zhong, Luna Liu, Adeyemi O. Adedeji, Pamela Chan, Melissa M. Schutten, Amrita V. Kamath & Meric A. Ovacik. (2022) Nonclinical Pharmacokinetics, Pharmacodynamics, and Translational Model of RO7297089, A Novel Anti-BCMA/CD16A Bispecific Tetravalent Antibody for the Treatment of Multiple Myeloma. The AAPS Journal 24:6.
Crossref
Iftekhar Mahmood. (2022) A Simple Method for the Prediction of Human Concentration–Time Profiles and Pharmacokinetics of Antibody–Drug Conjugates (ADC) from Rats or Monkeys. Antibodies 11:2, pages 42.
Crossref
Diana H. Marcantonio, Andrew Matteson, Marc Presler, John M. Burke, David R. Hagen, Fei Hua & Joshua F. Apgar. (2022) Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions. Frontiers in Pharmacology 13.
Crossref
Yurong Lai, Xiaoyan Chu, Li Di, Wei Gao, Yingying Guo, Xingrong Liu, Chuang Lu, Jialin Mao, Hong Shen, Huaping Tang, Cindy Q. Xia, Lei Zhang & Xinxin Ding. (2022) Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. Acta Pharmaceutica Sinica B 12:6, pages 2751-2777.
Crossref
Kenta Haraya, Haruka Tsutsui, Yasunori Komori & Tatsuhiko Tachibana. (2022) Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation. Pharmaceuticals 15:5, pages 508.
Crossref
Min Zhu, Kara Olson, Jessica R. Kirshner, Masood Khaksar Toroghi, Hong Yan, Lauric Haber, Craig Meagher, Dina M. Flink, Srikanth R. Ambati, John D. Davis, A. Thomas DiCioccio, Eric J. Smith & Marc W. Retter. (2022) Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies. Clinical and Translational Science 15:4, pages 954-966.
Crossref
Nicolas Frances, Marina Bacac, Katharine Bray-French, François Christen, Heather Hinton, Elisabeth Husar, Elizabeth Quackenbush, Martin Schäfer, Eginhard Schick, Arthur Van De Vyver & Wolfgang F. Richter. (2022) Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab. Journal of Pharmaceutical Sciences 111:4, pages 1208-1218.
Crossref
Ilaria Martinelli, Chiara Modica, Cristina Chiriaco, Cristina Basilico, James M. Hughes, Simona Corso, Silvia Giordano, Paolo M. Comoglio & Elisa Vigna. (2022) hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Hong Shen, Zheng Yang & A. David Rodrigues. (2022) Cynomolgus Monkey as an Emerging Animal Model to Study Drug Transporters: In Vitro, In Vivo, In Vitro-to-In Vivo Translation. Drug Metabolism and Disposition 50:3, pages 299-319.
Crossref
Daniela Bumbaca Yadav, Kapil Gadkar & Isabel Figueroa. 2022. Haschek and Rousseaux's Handbook of Toxicologic Pathology. Haschek and Rousseaux's Handbook of Toxicologic Pathology 77 100 .
Sean P. Oosterholt & Oscar Della Pasqua. (2021) Population pharmacokinetics of raxibacumab in healthy adult subjects. British Journal of Clinical Pharmacology 87:12, pages 4718-4725.
Crossref
Sean P. Oosterholt & Oscar Della Pasqua. (2021) Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years. British Journal of Clinical Pharmacology 87:12, pages 4709-4717.
Crossref
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations 225 262 .
Emily Lee, Sarah Szvetecz, Ryan Polli, Angelo Grauel, Jayson Chen, Joyce Judge, Smita Jaiswal, Rie Maeda, Stephanie Schwartz, Bernd Voedisch, Mateusz Piksa, Chietara Japutra, Lingheswar Sadhasivam, Yiqin Wang, Ana Carrion, Sinan Isim, Jinsheng Liang, Thomas Nicholson, Hong Lei, Qing Fang, Michelle Steinkrauss, Dana Walker, Joel Wagner, Viviana Cremasco, Hui Qin Wang, Giorgio G. Galli, Brian Granda, Keith Mansfield, Quincey Simmons, Andrew Anh Nguyen & Nicole Vincent Jordan. (2021) PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancer. Scientific Reports 11:1.
Crossref
Chang Liu, Yeon Su Kim, John Hok-Nin Lowe & Shan Chung. (2021) A cell-based FcRn-dependent recycling assay for predictive pharmacokinetic assessment of therapeutic antibodies. Bioanalysis 13:14, pages 1135-1144.
Crossref
Renu Singh, Maria Moreno & Danica Stanimirovic. (2021) Comparison of Various Approaches to Translate Non-Linear Pharmacokinetics of Monoclonal Antibodies from Cynomolgus Monkey to Human. European Journal of Drug Metabolism and Pharmacokinetics 46:4, pages 555-567.
Crossref
Eun‐young Kwak, Min ju Kim, Jin hyun Park, Ha wook Jung & Myung Eun Jung. (2021) Target‐mediated drug disposition modeling of an anti‐TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics. Journal of Thrombosis and Haemostasis 19:6, pages 1425-1435.
Crossref
Iftekhar Mahmood. (2021) Clinical Pharmacology of Antibody-Drug Conjugates. Antibodies 10:2, pages 20.
Crossref
Katherine E. Harris, Kyle J. Lorentsen, Harbani K. Malik-Chaudhry, Kaitlyn Loughlin, Harish Medlari Basappa, Sharon Hartstein, Ghenima Ahmil, Nicole S. Allen, Brian C. Avanzino, Aarti Balasubramani, Andrew A. Boudreau, Karen Chang, Maria-Cristina Cuturi, Laura M. Davison, Dennis M. Ho, Suhasini Iyer, Udaya S. Rangaswamy, Preethi Sankaran, Ute Schellenberger, Roland Buelow & Nathan D. Trinklein. (2021) A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells. Scientific Reports 11:1.
Crossref
Bryan E. Jones, Patricia L. Brown-Augsburger, Kizzmekia S. Corbett, Kathryn Westendorf, Julian Davies, Thomas P. Cujec, Christopher M. Wiethoff, Jamie L. Blackbourne, Beverly A. HeinzDenisa FosterRichard E. Higgs, Deepa Balasubramaniam, Lingshu WangYi Zhang, Eun Sung Yang, Roza Bidshahri, Lucas KraftYuri Hwang, Stefanie ŽentelisKevin R. Jepson, Rodrigo GoyaMaia A. SmithDavid W. Collins, Samuel J. Hinshaw, Sean A. TychoDavide PellacaniPing Xiang, Krithika MuthuramanSolmaz SobhanifarMarissa H. PiperFranz J. TrianaJorg Hendle, Anna Pustilnik, Andrew C. AdamsShawn J. BerensRalph S. Baric, David R. MartinezRobert W. Cross, Thomas W. Geisbert, Viktoriya BorisevichOlubukola Abiona, Hayley M. Belli, Maren de Vries, Adil Mohamed, Meike Dittmann, Marie I. Samanovic, Mark J. MulliganJory A. GoldsmithChing-Lin Hsieh, Nicole V. Johnson, Daniel Wrapp, Jason S. McLellan, Bryan C. Barnhart, Barney S. Graham, John R. Mascola, Carl L. HansenEster Falconer. (2021) The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Science Translational Medicine 13:593.
Crossref
Gai Ayalon, Seung-Hye Lee, Oskar Adolfsson, Corinne Foo-AtkinsJasvinder K. Atwal, Mira BlendstrupHelen BoolerJoseph Bravo, Robert BrendzaFlavia BrunsteinRuby ChanPriya ChandraJessica A. CouchAkash Datwani, Barthélemy Demeule, Danielle DiCaraRich EricksonJames A. ErnstOded ForemanDongping He, Isidro Hötzel, Michael KeeleyMichael C. M. Kwok, Julien Lafrance-Vanasse, Han Lin, Yanmei LuWilman Luk, Paul Manser, Andreas MuhsHai NguAndrea PfeiferMaria Pihlgren, Gautham K. RaoKimberly Scearce-Levie, Stephen P. Schauer, William B. Smith, Hilda SolanoyEdmond Teng, Kristin R. WildsmithDaniela Bumbaca YadavYong Ying, Reina N. Fuji & Geoffrey A. Kerchner. (2021) Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease. Science Translational Medicine 13:593.
Crossref
Brian T. Welsh, Ryan Faucette, Sanela Bilic, Constance J. Martin, Thomas Schürpf, David Chen, Samantha Nicholls, Janice Lansita & Ashish Kalra. (2021) Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors. International Journal of Toxicology 40:3, pages 226-241.
Crossref
Shu-Chen Lu, Michelle Chen, Larissa Atangan, Elizabeth A. Killion, Renee Komorowski, Yuan Cheng, Chawita Netirojjanakul, James R. Falsey, Marina Stolina, Denise Dwyer, Clarence Hale, Shanaka Stanislaus, Todd Hager, Veena A. Thomas, John M. Harrold, David J. Lloyd & Murielle M. Véniant. (2021) GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys. Cell Reports Medicine 2:5, pages 100263.
Crossref
Yuki Noguchi, Kazuhisa Ozeki, Hiroaki Takesue & Hidetaka Akita. (2021) A cell based assay for evaluating binding and uptake of an antibody using hepatic nonparenchymal cells. Scientific Reports 11:1.
Crossref
Vittal Shivva, Martin Fink & Philip J. Lowe. (2021) Improving priors for human monoclonal antibody linear pharmacokinetic parameters by using half-lives from non-human primates. Journal of Pharmacokinetics and Pharmacodynamics 48:2, pages 295-303.
Crossref
Victor Yip, M. Violet Lee, Ola M. Saad, Shuguang Ma, S. Cyrus Khojasteh & Ben-Quan Shen. (2021) Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY®) Antibody–Drug Conjugate in Sprague Dawley Rats. Journal of Clinical Medicine 10:6, pages 1323.
Crossref
Sanghwan Ko, Migyeong Jo & Sang Taek Jung. (2021) Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering. BioDrugs 35:2, pages 147-157.
Crossref
Iftekhar Mahmood. (2021) Interspecies Scaling of Antibody–Drug Conjugates (ADC) for the Prediction of Human Clearance. Antibodies 10:1, pages 1.
Crossref
Brian Geist, Songmao Zheng & Yan Xu. 2021. Remington. Remington 437 462 .
Kenta Haraya & Tatsuhiko Tachibana. (2020) Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans. Clinical Pharmacokinetics 60:1, pages 111-120.
Crossref
Jerry Li, Mina Nikanjam, Coleen K. Cunningham, Elizabeth J. McFarland, Emily E. Coates, Katherine V. Houser, Bob C. Lin, Adrian B. McDermott, Britta Flach, Lucio Gama, Richard A. Koup, Barney S. Graham, John R. Mascola, Julie E. Ledgerwood & Edmund V. Capparelli. (2020) Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. Clinical Pharmacology & Therapeutics 109:1, pages 184-192.
Crossref
Kenta Yoshida, Anita Moein, Tobias Bittner, Susanne Ostrowitzki, Helen Lin, Lee Honigberg, Jin Y. Jin & Angelica Quartino. (2020) Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease. Alzheimer's Research & Therapy 12:1.
Crossref
Victor Yip, Isabel Figueroa, Brandon Latifi, Shab Masih, Carl Ng, Doug Leipold, Amrita Kamath & Ben-Quan Shen. (2020) Anti–Lymphocyte Antigen 6 Complex, Locus E- Seco -Cyclopropabenzindol-4-One-Dimer Antibody-Drug Conjugate That Forms Adduct with α 1-Microglobulin Demonstrates Slower Systemic Antibody Clearance and Reduced Tumor Distribution in Animals . Drug Metabolism and Disposition 48:12, pages 1247-1256.
Crossref
Samuel M. PoloyacRichard J. BertzLee A. McDermottPunit Marathe. (2020) Pharmacological Optimization for Successful Traumatic Brain Injury Drug Development. Journal of Neurotrauma 37:22, pages 2435-2444.
Crossref
Renu Singh, Alexander Kozhich, Chin Pan, Francis Lee, Pina Cardarelli, Rangan Vangipuram, Rama Iyer & Punit Marathe. (2020) A novel semi‐mechanistic tumor growth fraction model for translation of preclinical efficacy of anti‐glypican 3 antibody drug conjugate to human. Biopharmaceutics & Drug Disposition 41:8-9, pages 319-333.
Crossref
Yuki Noguchi, Kazuhisa Ozeki & Hidetaka Akita. (2020) Pharmacokinetic prediction of an antibody in mice based on an in vitro cell-based approach using target receptor-expressing cells. Scientific Reports 10:1.
Crossref
Junsheng Xue, Daming Kong, Ye Yao, Liang Yang, Qingyu Yao, Yi Zhu, Yang Ding, Fen Yang, Jifang Gong, Lin Shen & Tianyan Zhou. (2020) Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody. Journal of Pharmaceutical Sciences 109:10, pages 3172-3180.
Crossref
Sheila Annie Peters, Carl Petersson, Andree Blaukat, Joern-Peter Halle & Hugues Dolgos. (2020) Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies. Drug Discovery Today 25:5, pages 909-919.
Crossref
Antonia Richter, Karina Knorr, Martin Schlapschy, Stephanie Robu, Volker Morath, Claudia Mendler, Hsi-Yu Yen, Katja Steiger, Marion Kiechle, Wolfgang Weber, Arne Skerra & Markus Schwaiger. (2020) First In-Human Medical Imaging with a PASylated 89Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer. Nuclear Medicine and Molecular Imaging 54:2, pages 114-119.
Crossref
Laura Bonifacio, Michael Dodds, David Prohaska, Aaron Moss, Amato Giaccia, Ray Tabibiazar & Gail McIntyre. (2019) Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500. Clinical and Translational Science 13:1, pages 204-211.
Crossref
Zheng Lu, Rüdiger Kaspera, Yoichi Naritomi & Tianli Wang. 2020. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology 671 681 .
Hans Peter Grimm, Eginhard Schick, Dominik Hainzl, Nicole Justies, Li Yu, Christian Klein, Elisabeth Husar & Wolfgang F. Richter. (2019) PKPD Assessment of the Anti-CD20 Antibody Obinutuzumab in Cynomolgus Monkey is Feasible Despite Marked Anti-Drug Antibody Response in This Species. Journal of Pharmaceutical Sciences 108:11, pages 3729-3736.
Crossref
Dongwei Li, Donna Lee, Randall C. Dere, Bing Zheng, Shang‐Fan Yu, Franklin K. Fuh, Katherine R. Kozak, Shan Chung, Daniela Bumbaca Yadav, Denise Nazzal, Dimitry Danilenko, Mary Ann T. Go, Marna Williams, Andrew G. Polson, Kirsten Achilles Poon & Saileta Prabhu. (2019) Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin. British Journal of Pharmacology 176:19, pages 3805-3818.
Crossref
Hannah M. Jones, Zhiwei Zhang, Paul Jasper, Haobin Luo, Lindsay B. Avery, Lindsay E. King, Hendrik Neubert, Hugh A. Barton, Alison M. Betts & Robert Webster. (2019) A Physiologically‐Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data . CPT: Pharmacometrics & Systems Pharmacology 8:10, pages 738-747.
Crossref
Ting-Ting Zhang, Junli Ma, Kenneth R. Durbin, Timothy Montavon, Susan E. Lacy, Gary J. Jenkins, Stella Doktor & J. Cory Kalvass. (2019) Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies. The AAPS Journal 21:5.
Crossref
Chunze Li, Cindy Zhang, Rong Deng, Douglas Leipold, Dongwei Li, Brandon Latifi, Yuying Gao, Crystal Zhang, Zao Li, Dale Miles, Shang‐Chiung Chen, Divya Samineni, Bei Wang, Priya Agarwal, Dan Lu, Saileta Prabhu, Sandhya Girish & Amrita V. Kamath. (2019) Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data. Clinical and Translational Science 12:5, pages 534-544.
Crossref
Mark Stroh, Jason Sagert, John M. Burke, Joshua F. Apgar, Lin Lin, Bjorn L. Millard & W. Michael Kavanaugh. (2019) Quantitative Systems Pharmacology Model of a Masked, Tumor‐Activated Antibody. CPT: Pharmacometrics & Systems Pharmacology 8:9, pages 676-684.
Crossref
Sameed Ahmed, Miandra Ellis, Hongshan Li, Luca Pallucchini & Andrew M. Stein. (2019) Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems. Journal of Pharmacokinetics and Pharmacodynamics 46:3, pages 287-304.
Crossref
Hiroko Tabuchi, Toshinori Katsurabara, Masahiko Mori, Muneo Aoyama, Takashi Obara, Nobuyuki Yasuda, Tetsu Kawano, Toshio Imai, Ichiro Ieiri & Yuji Kumagai. (2018) Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double‐Blind, Placebo‐Controlled Single‐Ascending‐Dose Study. The Journal of Clinical Pharmacology 59:5, pages 688-701.
Crossref
Honghui Zhou & Diane R. MouldHaiqing Wang, Zheng Yang & Rong Shi. 2019. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases 65 91 .
Douglas Leipold & Saileta Prabhu. (2018) Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies. Clinical and Translational Science 12:2, pages 130-139.
Crossref
Andrew T. Lucas, Ryan Robinson, Allison N. Schorzman, Joseph A. Piscitelli, Juan F. Razo & William C. Zamboni. (2019) Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. Antibodies 8:1, pages 3.
Crossref
Tommy Li & Joseph P. Balthasar. (2019) Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effects of FcRn Inhibitors in Mice, Rats, and Monkeys. Journal of Pharmaceutical Sciences 108:1, pages 701-713.
Crossref
Rong Deng, C. Andrew Boswell, Wendy S. Putnam, Meina T. Tang, Amit Garg, Chunze Li, Shan Chung & Sandhya Girish. 2019. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology 151 190 .
Bernd Meibohm. 2019. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology 105 137 .
Deni Hardiansyah & Chee Meng Ng. (2018) Minimal physiologically-based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti-VEGF humanized IgG1 antibody in cynomolgus monkey. European Journal of Pharmaceutical Sciences 125, pages 130-141.
Crossref
Konstantinos Biliouris, Ivan Nestorov, Himanshu Naik, David Dai, Guangqing Xiao, Qin Wang, Alex Pellerin, Dania Rabah, Lawrence J. Lesko & Mirjam N. Trame. (2018) A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans. Journal of Pharmacokinetics and Pharmacodynamics 45:6, pages 817-827.
Crossref
Aurelia H. M. de Vries Schultink, Robert P. Doornbos, Alexander B. H. Bakker, Kees Bol, Mark Throsby, Cecile Geuijen, David Maussang, Jan H. M. Schellens, Jos H. Beijnen & Alwin D. R. Huitema. (2018) Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose. Investigational New Drugs 36:6, pages 1006-1015.
Crossref
Donna W. Lee, Shelly Zhong, Rama Pai, Julie Rae, Siddharth Sukumaran, Eric G. Stefanich, Jeff Lutman, Estelle Doudement, Xiaoting Wang, Brandon Harder, Annemarie Lekkerkerker, Ann Herman, Wenjun Ouyang & Dimitry M. Danilenko. (2018) Nonclinical safety assessment of a human interleukin‐22 FC IG  fusion protein demonstrates in vitro to in vivo and cross‐species translatability . Pharmacology Research & Perspectives 6:6.
Crossref
Meric Ovacik & Kedan Lin. (2018) Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. Clinical and Translational Science 11:6, pages 540-552.
Crossref
Teerachat Saeheng, Kesara Na-Bangchang & Juntra Karbwang. (2018) Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review. European Journal of Clinical Pharmacology 74:11, pages 1365-1376.
Crossref
Nicole A. Kratochwil, Stephen R. Dueker, Dieter Muri, Claudia Senn, HyeJin Yoon, Byung-Yong Yu, Gwan-Ho Lee, Feng Dong & Michael B. Otteneder. (2018) Nanotracing and cavity-ring down spectroscopy: A new ultrasensitive approach in large molecule drug disposition studies. PLOS ONE 13:10, pages e0205435.
Crossref
Yuwei Deng, Li Hu, Wei Qiang, Zeneng Cheng, Lei Wang & Xiaoxia Wang. (2018) TNF-α level affects etanercept clearance: TNF-α concentration as a new correction factor of allometric scaling to predict individual etanercept clearances in patients with ankylosing spondylitis. Clinical and Experimental Pharmacology and Physiology 45:7, pages 643-651.
Crossref
Eric G. Stefanich, Julie Rae, Siddharth Sukumaran, Jeff Lutman, Annemarie Lekkerkerker, Wenjun Ouyang, Xiaoting Wang, Donna Lee, Dimitry M. Danilenko, Lauri Diehl, Kelly M. Loyet & Ann Herman. (2018) Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases. Biochemical Pharmacology 152, pages 224-235.
Crossref
Gregory Z. Ferl, Arthur Reyes, Liping L. Sun, Melissa Cheu, Amy Oldendorp, Saroja Ramanujan & Eric G. Stefanich. (2018) A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clinical and Translational Science 11:3, pages 296-304.
Crossref
Yan Weng, Tetsuya Ishino, Annette Sievers, Saswata Talukdar, Jeffrey R. Chabot, Amy Tam, Weili Duan, Kelvin Kerns, Eric Sousa, Tao He, Alison Logan, Darwin Lee, Dongmei Li, Yingjiang Zhou, Barbara Bernardo, Alison Joyce, Mania Kavosi, Denise M. O’Hara, Tracey Clark, Jie Guo, Craig Giragossian, Mark Stahl, Roberto A. Calle, Ron Kriz, Will Somers & Laura Lin. (2018) Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing. Scientific Reports 8:1.
Crossref
Paul J. Carter & Greg A. Lazar. (2017) Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nature Reviews Drug Discovery 17:3, pages 197-223.
Crossref
Hanne Kinnunen Bown, Catherine Bonn, Stefan Yohe, Daniela Bumbaca Yadav, Thomas W. Patapoff, Ann Daugherty & Randall J. Mrsny. (2018) In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies. Journal of Controlled Release 273, pages 13-20.
Crossref
Gary Mo, John R. Baldwin, Debra Luffer-Atlas, Robert L. Ilaria, Ilaria Conti, Michael Heathman & Damien M. Cronier. (2017) Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer. Clinical Pharmacokinetics 57:3, pages 355-365.
Crossref
Liming Liu. (2017) Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein & Cell 9:1, pages 15-32.
Crossref
Zheng Lu, Rüdiger Kaspera, Yoichi Naritomi & Tianli Wang. 2018. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology 1 11 .
Miro J. Eigenmann, Tine V. Karlsen, Ben‐Fillippo Krippendorff, Olav Tenstad, Ludivine Fronton, Michael B. Otteneder & Helge Wiig. (2017) Interstitial IgG antibody pharmacokinetics assessed by combined in vivo ‐ and physiologically‐based pharmacokinetic modelling approaches . The Journal of Physiology 595:24, pages 7311-7330.
Crossref
O. S. Qureshi, T. F. Rowley, F. Junker, S. J. Peters, S. Crilly, J. Compson, A. Eddleston, H. Björkelund, K. Greenslade, M. Parkinson, N. L. Davies, R. Griffin, T. L. Pither, K. Cain, L. Christodoulou, L. Staelens, E. Ward, J. Tibbitts, A. Kiessling, B. Smith, F. R. Brennan, M. Malmqvist, F. Fallah-Arani & D. P. Humphreys. (2017) Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions. Scientific Reports 7:1.
Crossref
Takahiro Ishiguro, Yuji SanoShun-ichiro KomatsuMika Kamata-Sakurai, Akihisa Kaneko, Yasuko KinoshitaHirotake ShiraiwaYumiko AzumaToshiaki TsunenariYoko KayukawaYukiko SonobeNatsuki OnoKiyoaki SakataToshihiko FujiiYoko MiyazakiMizuho NoguchiMika EndoAsako HaradaWerner Frings, Etsuko FujiiEitaro Nanba, Atsushi NaritaAkihisa SakamotoTetsuya Wakabayashi, Hiroko KonishiHiroaki SegawaTomoyuki Igawa, Takashi TsushimaHironori Mutoh, Yukari Nishito, Mina TakahashiLorraine Stewart, Ehab ElGabryYoshiki Kawabe, Masaki IshigaiShuichi Chiba, Masahiro Aoki, Kunihiro HattoriJunichi Nezu. (2017) An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors. Science Translational Medicine 9:410.
Crossref
Chuenlei Parng, Victoria Markiewicz, Jianqing Chen, Beth Leary, Nicole Duriga, Lisa Dyleski, Teresa Caiazzo, Michael Bolt, Alison Joyce, Boris Gorovits, Debra D. Pittman & Robert Webster. (2017) Preclinical Pharmacokinetics, Pharmacodynamics, Tissue Distribution, and Interspecies Scaling of Recombinant Human Coagulation Factor Xa I16L. Journal of Pharmaceutical Sciences 106:8, pages 2136-2143.
Crossref
Kenta Haraya, Tatsuhiko Tachibana & Junichi Nezu. (2017) Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human. Drug Metabolism and Pharmacokinetics 32:4, pages 208-217.
Crossref
Eugenia Z. Ong, Yadunanda Budigi, Hwee Cheng Tan, Luke N. Robinson, Kirk J. Rowley, Alexander Winnett, Sven Hobbie, Zachary Shriver, Gregory J. Babcock & Eng Eong Ooi. (2017) Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates. Antiviral Research 144, pages 44-47.
Crossref
Jian-Ming Gu, Xiao-Yan Zhao, Thomas Schwarz, Joachim Schuhmacher, Andreas Baumann, Elena Ho, Babu Subramanyan, Kathy Tran, Timothy Myles, Chandra Patel & Maria Koellnberger. (2017) Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys. The AAPS Journal 19:4, pages 1186-1195.
Crossref
Aman P. Singh & Dhaval K. Shah. (2017) Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). The AAPS Journal 19:4, pages 1054-1070.
Crossref
Ivo P. Nnane, Chao Han, Qun Jiao, Susan H. Tam, Hugh M. Davis & Zhenhua Xu. (2017) Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys. Basic & Clinical Pharmacology & Toxicology 121:1, pages 13-21.
Crossref
Marion Bouillon-Pichault, Claire Brillac, Céline Amara, Céline Nicolazzi, Nathalie Fagniez, Jean-Baptiste Fau, Kimiko Koiwai, Samira Ziti-Ljajic & Christine Veyrat-Follet. (2017) Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates. The Journal of Clinical Pharmacology 57:7, pages 865-875.
Crossref
Amanda Long, Emmanuel Chigutsa & Johan Wallin. (2016) Population Pharmacokinetics of Necitumumab in Cancer Patients. Clinical Pharmacokinetics 56:5, pages 505-514.
Crossref
Wan‐Su Park, Seunghoon Han, Jongtae Lee, Taegon Hong, Jonghwa Won, Yangmi Lim, Kyuhyun Lee, Han Yeul Byun & Dong‐Seok Yim. (2016) Use of a Target‐Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC 1118, an Anti‐epidermal Growth Factor Receptor Antibody . Basic & Clinical Pharmacology & Toxicology 120:3, pages 243-249.
Crossref
Siddharth Sukumaran, Crystal Zhang, Douglas D. Leipold, Ola M. Saad, Keyang Xu, Kapil Gadkar, Divya Samineni, Bei Wang, Marija Milojic-Blair, Montserrat Carrasco-Triguero, Bonnee Rubinfeld, Paul Fielder, Kedan Lin & Saroja Ramanujan. (2016) Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics. The AAPS Journal 19:1, pages 130-140.
Crossref
Xiang-Qing Yu, Gabriel J. Robbie, Yuling Wu, Mark T. Esser, Kathryn Jensen, Howard I. Schwartz, Terramika Bellamy, Martha Hernandez-Illas & Hasan S. Jafri. (2017) Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrobial Agents and Chemotherapy 61:1.
Crossref
Claire L. Dobson, Paul W. A. Devine, Jonathan J. Phillips, Daniel R. Higazi, Christopher Lloyd, Bojana Popovic, Joanne Arnold, Andrew Buchanan, Arthur Lewis, Joanne Goodman, Christopher F. van der Walle, Peter Thornton, Lisa Vinall, David Lowne, Anna Aagaard, Lise-Lotte Olsson, Anna Ridderstad Wollberg, Fraser Welsh, Theodoros K. Karamanos, Clare L. Pashley, Matthew G. Iadanza, Neil A. Ranson, Alison E. Ashcroft, Alistair D. Kippen, Tristan J. Vaughan, Sheena E. Radford & David C. Lowe. (2016) Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Scientific Reports 6:1.
Crossref
D Lu, L Gibiansky, P Agarwal, RC Dere, C Li, Y‐W Chu, J Hirata, A Joshi, JY Jin & S Girish. (2016) Integrated Two‐Analyte Population Pharmacokinetic Model for Antibody–Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling. CPT: Pharmacometrics & Systems Pharmacology 5:12, pages 665-673.
Crossref
Matthew P. Kosloski, Sandra Goss, Susanne X. Wang, Jia Liu, Ralf Loebbert, Jeroen K. Medema, Wei Liu & Sandeep Dutta. (2016) Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT-981 Against IL-1? and IL-1? in Healthy Subjects and Patients With Osteoarthritis of the Knee. The Journal of Clinical Pharmacology 56:12, pages 1582-1590.
Crossref
Sherri Dudal, Heather Hinton, Anna M. Giusti, Marina Bacac, Magali Muller, Tanja Fauti, Sara Colombetti, Tobias Heckel, Nicolas Giroud, Christian Klein, Pablo Umaña, Lisa Benincosa, Juergen Bachl, Thomas Singer & Katharine Bray-French. (2016) Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB. Journal of Immunotherapy 39:7, pages 279-289.
Crossref
Amrita V. Kamath. (2016) Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discovery Today: Technologies 21-22, pages 75-83.
Crossref
X Chen, N Haddish-Berhane, P Moore, T Clark, Y Yang, H Li, D Xuan, HA Barton, AM Betts & F Barletta. (2016) Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: An Integrated PK/PD Modeling Approach. Clinical Pharmacology & Therapeutics 100:3, pages 232-241.
Crossref
Diane R. Mould & Bernd Meibohm. (2016) Drug Development of Therapeutic Monoclonal Antibodies. BioDrugs 30:4, pages 275-293.
Crossref
A. G. de Lucas, A. J. Schuhmacher, M. Oteo, E. Romero, J. A. Cámara, A. de Martino, A. G. Arroyo, M. Á. Morcillo, M. Squatrito, J. L. Martinez-Torrecuadrada & F. Mulero. (2016) Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas. PLOS ONE 11:7, pages e0158634.
Crossref
Rama Pai, Ning Ma, Anu V. Connor, Dimitry M. Danilenko, Jacqueline M. Tarrant, Dany Salvail, Lisa Wong, Dylan P. Hartley, Dinah Misner, Eric Stefanich, Yan Wu, Yongmei Chen, Hong Wang & Donna M. Dambach. (2016) Therapeutic Antibody-Induced Vascular Toxicity Due to Off-Target Activation of Nitric Oxide in Cynomolgus Monkeys. Toxicological Sciences 151:2, pages 245-260.
Crossref
Matthieu Piccand, Juliana Bessa, Eginhard Schick, Claudia Senn, Carole Bourquin & Wolfgang F. Richter. (2015) Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice. The AAPS Journal 18:2, pages 354-361.
Crossref
Lei Wang, Wei Qiang & Zeneng Cheng. (2016) Allometric Scaling of Therapeutic Monoclonal Antibodies Using Antigen Concentration as a Correction Factor: Application to the Human Clearance Prediction. Journal of Pharmaceutical Sciences 105:3, pages 1335-1340.
Crossref
Gregory Z. Ferl, Frank‐Peter Theil & Harvey Wong. (2016) Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini‐review on fundamental concepts and applications. Biopharmaceutics & Drug Disposition 37:2, pages 75-92.
Crossref
Haiqing Wang, Vangipuram S. Rangan, Mei‐Chen Sung, David Passmore, Thomas Kempe, Xiaoli Wang, Lourdes Thevanayagam, Chin Pan, Chetana Rao, Mohan Srinivasan, Qian Zhang, Sanjeev Gangwar, Shrikant Deshpande, Pina Cardarelli, Punit Marathe & Zheng Yang. (2015) Pharmacokinetic characterization of BMS‐936561, an anti‐CD70 antibody‐drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans. Biopharmaceutics & Drug Disposition 37:2, pages 93-106.
Crossref
Jing Wang, Suhasini Iyer, Paul J. Fielder, John D. Davis & Rong Deng. (2015) Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. Biopharmaceutics & Drug Disposition 37:2, pages 51-65.
Crossref
Peng Zou, Sau Lee, Min Li, Lawrence Yu & Duxin Sun. 2016. Pharmacokinetics in Drug Development. Pharmacokinetics in Drug Development 39 58 .
Andreas Baumann, Saileta Prabhu & Jitendra Kanodia. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 13 .
Theresa Yuraszeck & Megan Gibbs. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 15 .
Diane D. Wang, Justin T. Hoffman & Kourosh Parivar. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 17 .
Chao Han & Christina Lourdes Mayer. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 16 .
Jiunn H. Lin & Weirong Wang. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 10 .
Weirong Wang & Thomayant Prueksaritanont. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 11 .
Pratap Singh, Abhinav Tiwari, Anson Abraham & Anup Zutshi. 2015. Developability of Biotherapeutics. Developability of Biotherapeutics 109 134 .
Daniela Bumbaca Yadav, Vikas K. Sharma, Charles Andrew Boswell, Isidro Hotzel, Devin Tesar, Yonglei Shang, Yong Ying, Saloumeh K. Fischer, Jane L. Grogan, Eugene Y. Chiang, Konnie Urban, Sheila Ulufatu, Leslie A. Khawli, Saileta Prabhu, Sean Joseph & Robert F. Kelley. (2015) Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics. Journal of Biological Chemistry 290:50, pages 29732-29741.
Crossref
Kha N. Le, Leonid Gibiansky, Jeremy Good, Teresa Davancaze, Menno van Lookeren Campagne, Kelly M. Loyet, Alyssa Morimoto, Jin Jin, Lisa A. Damico-Beyer & William D. Hanley. (2015) A Mechanistic Pharmacokinetic/Pharmacodynamic Model of Factor D Inhibition in Cynomolgus Monkeys by Lampalizumab for the Treatment of Geographic Atrophy. Journal of Pharmacology and Experimental Therapeutics 355:2, pages 288-296.
Crossref
Y. Zhang, S. Doshi & M. Zhu. (2015) Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research. British Journal of Clinical Pharmacology 80:5, pages 957-964.
Crossref
Keith Wycoff, James Maclean, Archana Belle, Lloyd Yu, Y Tran, Chad Roy & Frederick Hayden. (2015) Anti‐infective immunoadhesins from plants. Plant Biotechnology Journal 13:8, pages 1078-1093.
Crossref
Jie Zhao, Yanguang Cao & William J. Jusko. (2015) Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model. Pharmaceutical Research 32:10, pages 3269-3281.
Crossref
Patrick M. Glassman, Yang Chen & Joseph P. Balthasar. (2015) Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys. Journal of Pharmacokinetics and Pharmacodynamics 42:5, pages 527-540.
Crossref
Sven Hoefman, Ingrid Ottevaere, Judith Baumeister & Maria Sargentini-Maier. (2015) Pre-Clinical Intravenous Serum Pharmacokinetics of Albumin Binding and Non-Half-Life Extended Nanobodies®. Antibodies 4:3, pages 141-156.
Crossref
Craig Giragossian, Chandra Vage, Jun Li, Kathleen Pelletier, Nicole Piché-Nicholas, Manoj Rajadhyaksha, Jennifer Liras, Alison Logan, Roberto A. Calle & Yan Weng. (2015) Mechanistic Investigation of the Preclinical Pharmacokinetics and Interspecies Scaling of PF-05231023, a Fibroblast Growth Factor 21–Antibody Protein Conjugate. Drug Metabolism and Disposition 43:6, pages 803-811.
Crossref
Aman P. Singh, Wojciech Krzyzanski, Steven W. Martin, Gregory Weber, Alison Betts, Alaa Ahmad, Anson Abraham, Anup Zutshi, John Lin & Pratap Singh. (2014) Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition. The AAPS Journal 17:2, pages 389-399.
Crossref
Ivo P. Nnane, Zhenhua Xu, Honghui Zhou & Hugh M. Davis. (2015) Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody. Basic & Clinical Pharmacology & Toxicology, pages n/a-n/a.
Crossref
Wai Siang Law, Jean-Christophe Genin, Christian Miess, Gwenola Treton, Andrew Paul Warren, Peter Lloyd, Sherri Dudal & Carsten Krantz. (2014) Use of generic LC–MS/MS assays to characterize atypical PK profile of a biotherapeutic monoclonal antibody. Bioanalysis 6:23, pages 3225-3235.
Crossref
Leonid Kagan, Jie Zhao & Donald E. Mager. (2014) Interspecies Pharmacokinetic Modeling of Subcutaneous Absorption of Rituximab in Mice and Rats. Pharmaceutical Research 31:12, pages 3265-3273.
Crossref
Atsushi Muto, Kazutaka Yoshihashi, Minako Takeda, Takehisa Kitazawa, Tetsuhiro Soeda, Tomoyuki Igawa, Zenjiro Sampei, Taichi Kuramochi, Akihisa Sakamoto, Kenta Haraya, Kenji Adachi, Yoshiki Kawabe, Keiji Nogami, Midori Shima & Kunihiro Hattori. (2014) Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 124:20, pages 3165-3171.
Crossref
Wim Dokter, Ruud Ubink, Miranda van der Lee, Monique van der Vleuten, Tanja van Achterberg, Danielle Jacobs, Eline Loosveld, Diels van den Dobbelsteen, David Egging, Ellen Mattaar, Patrick Groothuis, Patrick Beusker, Ruud Coumans, Ronald Elgersma, Wiro Menge, John Joosten, Henri Spijker, Tijl Huijbregts, Vincent de Groot, Michel Eppink, Guy de Roo, Gijs Verheijden & Marco Timmers. (2014) Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform. Molecular Cancer Therapeutics 13:11, pages 2618-2629.
Crossref
Leonid Kagan. (2014) Pharmacokinetic Modeling of the Subcutaneous Absorption of Therapeutic Proteins. Drug Metabolism and Disposition 42:11, pages 1890-1905.
Crossref
Bo An, Ming Zhang & Jun Qu. (2014) Toward Sensitive and Accurate Analysis of Antibody Biotherapeutics by Liquid Chromatography Coupled with Mass Spectrometry. Drug Metabolism and Disposition 42:11, pages 1858-1866.
Crossref
S Zheng, P Gaitonde, M A Andrew, M A Gibbs, L J Lesko & S Schmidt. (2014) Model-Based Assessment of Dosing Strategies in Children for Monoclonal Antibodies Exhibiting Target-Mediated Drug Disposition. CPT: Pharmacometrics & Systems Pharmacology 3:10, pages 138.
Crossref
Brendan Bender, Douglas D. Leipold, Keyang Xu, Ben-Quan Shen, Jay Tibbitts & Lena E. Friberg. (2014) A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer. The AAPS Journal 16:5, pages 994-1008.
Crossref
Chunsheng Li, Junying Wang, Jia Hu, Yi Feng, Kosei Hasegawa, Xiaohui Peng, Xingmei Duan, Aizhi Zhao, John L. Mikitsh, Vladimir R. Muzykantov, Ann-Marie Chacko, Daniel A. Pryma, Steven M. Dunn & George Coukos. (2014) Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. Oncotarget 5:16, pages 6994-7012.
Crossref
Xingrong Liu, Ying C. Ou, Jun Zhang, Ago Ahene, Douglas Clark, Su-Chun Hsieh, Matthew Cooper & Changhua Ji. (2013) Pharmacokinetics and Pharmacodynamics of CD4-Anchoring Bi-Functional Fusion Inhibitor in Monkeys. Pharmaceutical Research 31:3, pages 809-818.
Crossref
A. Muto, K. Yoshihashi, M. Takeda, T. Kitazawa, T. Soeda, T. Igawa, Y. Sakamoto, K. Haraya, Y. Kawabe, M. Shima, A. Yoshioka & K. Hattori. (2014) Anti‐factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. Journal of Thrombosis and Haemostasis 12:2, pages 206-213.
Crossref
Joanne GoodmanBalaji Agoram. (2013) Analytical assay platforms for soluble target engagement biomarkers: old favorites and emerging technologies. Bioanalysis 5:23, pages 2919-2931.
Crossref
C. H. Lieu, A.-C. Tan, S. Leong, J. R. Diamond & S. G. Eckhardt. (2013) From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development. JNCI Journal of the National Cancer Institute 105:19, pages 1441-1456.
Crossref
Nahor Haddish-Berhane, Dhaval K. Shah, Dangshe Ma, Mauricio Leal, Hans-Peter Gerber, Puja Sapra, Hugh A. Barton & Alison M. Betts. (2013) On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. Journal of Pharmacokinetics and Pharmacodynamics 40:5, pages 557-571.
Crossref
Hong Xiang, Brendan C. Bender, Arthur E. ReyesIIII, Mark Merchant, Nelson L. ‘Shasha’ Jumbe, Mally Romero, Teresa Davancaze, Ihsan Nijem, Elaine Mai, Judy Young, Amy Peterson & Lisa A. Damico-Beyer. (2013) Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development. Clinical Cancer Research 19:18, pages 5068-5078.
Crossref
Leijun Hu & Ryan J. Hansen. (2013) Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies. Journal of Pharmaceutical Sciences 102:9, pages 2898-2908.
Crossref
Hong Xiang, Arthur E. ReyesIIII, Steve Eppler, Sean Kelley & Lisa A. Damico-Beyer. (2013) Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration–effect relationship support clinical dose and regimen selection. Cancer Chemotherapy and Pharmacology 72:2, pages 405-415.
Crossref
Matthew P. Kosloski, Dipak S. Pisal, Donald E. Mager & Sathy V. Balu-Iyer. (2013) Allometry of Factor VIII and Informed Scaling of Next-Generation Therapeutic Proteins. Journal of Pharmaceutical Sciences 102:7, pages 2380-2394.
Crossref
Dan Lu, Sandhya Girish, Frank‐Peter Theil & Amita Joshi. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 34 .
Kathryn L. Chapman, Henry Holzgrefe, Lauren E. Black, Marilyn Brown, Gary Chellman, Christine Copeman, Jessica Couch, Stuart Creton, Sean Gehen, Alan Hoberman, Lewis B. Kinter, Stephen Madden, Charles Mattis, Hugh A. Stemple & Stephen Wilson. (2013) Pharmaceutical toxicology: Designing studies to reduce animal use, while maximizing human translation. Regulatory Toxicology and Pharmacology 66:1, pages 88-103.
Crossref
Kenneth T. Luu, Eugenia Kraynov, Bing Kuang, Paolo Vicini & Wei-Zhu Zhong. (2013) Modeling, Simulation, and Translation Framework for the Preclinical Development of Monoclonal Antibodies. The AAPS Journal 15:2, pages 551-558.
Crossref
Takayuki Sakurai, Ryo Takai, Heinrich Bürgin, Akifumi Shioda, Yuichiro Sakamoto, Jun Amano, Hans Peter Grimm, Wolfgang F. Richter, Yoshinobu Higuchi, Shuichi Chiba, Akinori Kawamura, Masami Suzuki & Lutz Müller. (2013) The Effects of Interleukin-6 Signal Blockade on Immune System, Reproductive and Skeletal Development in Juvenile Mice. Birth Defects Research Part B: Developmental and Reproductive Toxicology 98:2, pages 170-182.
Crossref
Zenjiro Sampei, Tomoyuki Igawa, Tetsuhiro Soeda, Yukiko Okuyama-Nishida, Chifumi Moriyama, Tetsuya Wakabayashi, Eriko Tanaka, Atsushi Muto, Tetsuo Kojima, Takehisa Kitazawa, Kazutaka Yoshihashi, Aya Harada, Miho Funaki, Kenta Haraya, Tatsuhiko Tachibana, Sachiyo Suzuki, Keiko Esaki, Yoshiaki Nabuchi & Kunihiro Hattori. (2013) Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity. PLoS ONE 8:2, pages e57479.
Crossref
M. Schrag & K. Regal. 2013. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. A Comprehensive Guide to Toxicology in Nonclinical Drug Development 69 106 .
Rodney A. Prell, Donna W. Lee, Wendy G. Halpern & Anu V. Connor. 2013. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics 343 371 .
Melinda Marian & Wolfgang Seghezzi. 2013. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics 97 137 .
Michael Schrag & Kelly Regal. 2013. A Comprehensive Guide to Toxicology in Preclinical Drug Development. A Comprehensive Guide to Toxicology in Preclinical Drug Development 31 68 .

Displaying 200 of 217 citing articles. Use the download link below to view the full list of citing articles.

Download full citations list

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.